

Elizabeth A Griffiths

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2532850/publications.pdf>

Version: 2024-02-01

77
papers

3,817
citations

236925

25
h-index

128289

60
g-index

78
all docs

78
docs citations

78
times ranked

8422
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutant <i>PPM1D</i> - and <i>TP53</i> -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. <i>JCO Precision Oncology</i> , 2022, 6, e2100309.	3.0	15
2	Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. <i>Blood Advances</i> , 2022, 6, 2835-2846.	5.2	8
3	Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia. <i>Blood</i> , 2022, 139, 2842-2846.	1.4	9
4	Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. <i>Blood</i> , 2022, 140, 285-289.	1.4	15
5	A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 113-118.	0.4	4
6	Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG-M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1778-1781.	1.3	2
7	Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. <i>Blood</i> , 2021, 138, 811-814.	1.4	81
8	Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 15004.	3.3	4
9	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	7.1	149
10	Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution. <i>Cancer Cell</i> , 2021, 39, 1045-1047.	16.8	46
11	A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia. <i>Leukemia Research</i> , 2021, 107, 106588.	0.8	3
12	Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 4646.	3.7	8
13	Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 394-404.	2.3	2
14	Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4435-4435.	1.4	1
15	Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4426-4426.	1.4	0
16	Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients. <i>Blood</i> , 2021, 138, 4066-4066.	1.4	0
17	Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis. <i>Blood</i> , 2021, 138, 1264-1264.	1.4	5
18	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. <i>Scientific Reports</i> , 2021, 11, 23284.	3.3	3

#	ARTICLE	IF	CITATIONS
19	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	4.6	56
20	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	16.8	26
21	A case study of 10 patients administered HBOCâ€²01 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option. <i>Transfusion</i> , 2020, 60, 932-939.	1.6	11
22	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	13.7	1,395
23	Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells. <i>Leukemia</i> , 2020, 34, 2460-2472.	7.2	7
24	Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. <i>Leukemia Research</i> , 2020, 91, 106339.	0.8	20
25	BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting. <i>Blood Reviews</i> , 2020, 43, 100654.	5.7	12
26	Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
27	Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
28	Treatment of CD19â€²positive mixed phenotype acute leukemia with blinatumomab. <i>American Journal of Hematology</i> , 2019, 94, E7-E8.	4.1	19
29	Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS). <i>Blood</i> , 2019, 134, 566-566.	1.4	7
30	Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study. <i>Blood</i> , 2019, 134, 3501-3501.	1.4	1
31	Quantification of Humoral Immune Response to Influenza Vaccination in MDS. <i>Blood</i> , 2019, 134, 4756-4756.	1.4	2
32	Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis. <i>Blood</i> , 2019, 134, 3866-3866.	1.4	0
33	Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2011-2013.	1.3	7
34	To chelate or not to chelate in MDS: That is the question!. <i>Blood Reviews</i> , 2018, 32, 368-377.	5.7	25
35	NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. <i>Clinical Cancer Research</i> , 2018, 24, 1019-1029.	7.0	87
36	Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience. <i>Leukemia Research</i> , 2018, 75, 29-35.	0.8	20

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2677-2677.	1.4	1
38	Cost reduction associated with heparin-induced thrombocytopenia panel ordering for enoxaparin versus heparin for prophylactic and therapeutic use: A retrospective analysis in a community hospital setting. <i>Avicenna Journal of Medicine</i> , 2018, 8, 133-138.	0.8	1
39	Genome Wide Association Analyses Identify Pleiotropic Variants Associated with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Susceptibility. <i>Blood</i> , 2018, 132, 1500-1500.	1.4	0
40	Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes. <i>Blood</i> , 2018, 132, 4366-4366.	1.4	0
41	Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia. <i>Leukemia Research Reports</i> , 2017, 7, 36-39.	0.4	12
42	Guadecitabine (SGI-110) in treatment-naïve patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1317-1326.	10.7	148
43	Swallowing a bitter pill—oral arsenic trioxide for acute promyelocytic leukemia. <i>Blood Reviews</i> , 2016, 30, 201-211.	5.7	22
44	A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia. <i>Leukemia Research</i> , 2016, 43, 44-48.	0.8	10
45	Epigenetics: A primer for clinicians. <i>Blood Reviews</i> , 2016, 30, 285-295.	5.7	42
46	Polo-like kinase inhibitors in hematologic malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 200-210.	4.4	29
47	Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. <i>Oncotarget</i> , 2016, 7, 12840-12856.	1.8	63
48	Vaccination with NY-ESO-1 in Combination with Decitabine for Patients with MDS. <i>Blood</i> , 2016, 128, 4326-4326.	1.4	1
49	Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. <i>BMC Genomics</i> , 2015, 16, 727.	2.8	42
50	Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old. <i>American Journal of Hematology</i> , 2015, 90, 639-646.	4.1	31
51	Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, E77-9.	4.1	69
52	Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. <i>Blood Reviews</i> , 2015, 29, 243-249.	5.7	42
53	How we will treat chronic myeloid leukemia in 2016. <i>Blood Reviews</i> , 2015, 29, 137-142.	5.7	15
54	Pharmacological targeting of β -catenin in normal karyotype acute myeloid leukemia blasts. <i>Haematologica</i> , 2015, 100, e49-e52.	3.5	16

#	ARTICLE	IF	CITATIONS
55	Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. <i>Epigenetics</i> , 2015, 10, 237-246.	2.7	64
56	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1099-1110.	10.7	249
57	Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S73-S79.	0.4	44
58	Bosutinib for the treatment of Philadelphia chromosome-positive leukemias. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 599-608.	0.8	3
59	CLAG±M (cladribine, cytarabine, granulocyte colony stimulating factor ± mitoxantrone) Results in High Response Rates in Older Patients with Secondary and Relapsed/Refractory Acute Myeloid Leukemia - a Single Institute Experience. <i>Blood</i> , 2015, 126, 1341-1341.	1.4	1
60	Induction of Cancer Testis Antigen Expression in Circulating Acute Myeloid Leukemia Blasts Following Hypomethylating Agent Monotherapy. <i>Blood</i> , 2015, 126, 2537-2537.	1.4	0
61	Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2536-2536.	1.4	0
62	Regulation of the Interferon regulatory factor-8 (IRF-8) Tumor Suppressor Gene by the Signal Transducer and Activator of Transcription 5 (STAT5) Transcription Factor in Chronic Myeloid Leukemia. <i>Journal of Biological Chemistry</i> , 2014, 289, 15642-15652.	3.4	27
63	Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. <i>Leukemia Research</i> , 2014, 38, 1332-1341.	0.8	77
64	Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 37-49.	3.4	168
65	High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure. <i>Leukemia Research Reports</i> , 2014, 3, 62-66.	0.4	7
66	Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature. <i>Leukemia Research</i> , 2013, 37, 894-899.	0.8	66
67	Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. <i>Leukemia Research</i> , 2013, 37, 1468-1471.	0.8	7
68	Epigenetic Therapies in MDS and AML. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, 253-283.	1.6	52
69	First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 497-497.	1.4	23
70	Conventional Dose Hypomethylating Agents Induce CG Antigen Genes In Vivo. <i>Blood</i> , 2011, 118, 2441-2441.	1.4	1
71	Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients.. <i>Blood</i> , 2010, 116, 1041-1041.	1.4	4
72	DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes. <i>Seminars in Hematology</i> , 2008, 45, 23-30.	3.4	203

#	ARTICLE	IF	CITATIONS
73	DNA methyltransferase inhibitors: Class effect or unique agents?. Leukemia and Lymphoma, 2008, 49, 650-651.	1.3	10
74	Acute Myeloid Leukemia Is Characterized by Wnt Pathway Inhibitor Promoter Methylation.. Blood, 2008, 112, 2253-2253.	1.4	1
75	Differences in Promoter Methylation of Tumor Suppressor Genes in Cytogenetically Normal and Abnormal Acute Myeloid Leukemias.. Blood, 2008, 112, 2249-2249.	1.4	0
76	In Vivo Effects of Bifidobacteria and Lactoferrin on Gut Endotoxin Concentration and Mucosal Immunity in Balb/c Mice. Digestive Diseases and Sciences, 2004, 49, 579-589.	2.3	171
77	In vitro growth responses of bifidobacteria and enteropathogens to bovine and human lactoferrin. Digestive Diseases and Sciences, 2003, 48, 1324-1332.	2.3	30